Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant Clinical Trial

Official title:

Time Restricted Feeding in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04534985
• Other study ID #: 20-1262
• Status: Completed
• Phase: N/A
• Start date: February 9, 2021
• Est. completion date: March 31, 2023

Study information

• Verified date: April 2023
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed research will determine the feasibility of a time restricted feeding intervention,a fasting regimen that restricts eating to a feeding window (8 hrs/day) for 1 year in adults with autosomal dominant polycystic kidney disease (ADPKD) who are overweight or obese. The study will provide valuable information on the intervention in terms of safety, adherence, acceptability, and tolerability. Last, this pilot trial will provide initial insight into biological changes including abdominal adiposity, changes in kidney growth and function, and markers of biological pathways related to the intervention.

Description:

Mounting evidence suggests that a metabolic defect exists in autosomal dominant polycystic kidney disease (ADPKD), which likely contributes to cystic epithelial proliferation and subsequent cyst growth. There are notable overlapping features and pathways among metabolism, obesity, and/or ADPKD. The investigators recently reported that in the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Study A that overweight and obesity are strong independent predictors of more rapid kidney growth. Moving beyond body mass index, the investigators have novel preliminary data using magnetic resonance images (MRIs) from a small number of participants from HALT-PKD Study A that abdominal adiposity is an independent predictor of kidney growth and kidney function decline. Adipocytes do not simply act as a fat reservoir but are active endocrine organs that promote release of pro-inflammatory cytokines and produce adipokines. Numerous signaling pathways promoted by adipocytes are also implicated in cystogenesis. Periods of fasting may counter adiposity-mediated signaling pathways and slow ADPKD progression. Mild-to-moderate food restriction profoundly slows cyst growth and maintains renal function in rodent models of ADPKD, which are characterized by metabolic reprogramming favoring enhanced aerobic glycolysis. Notably, fasting promotes a shift from carbohydrate to fat metabolism, which could suppress cyst growth. The investigators are currently conducting an ongoing behavioral weight loss pilot trial (based on either daily caloric restriction or intermittent fasting) in adults with ADPKD who are overweight/obese. As an alternative to these approaches, time-restricted feeding (TRF) is a novel fasting regimen that restricts eating to a feeding window (typically 8-12 hrs/day). As isocaloric TRF reduces disease progression in a rodent model of ADPKD, including kidney: body weight and mammalian target of rapamycin (mTOR) activity, it may be an alternative and easier to adhere to dietary strategy to slow ADPKD progression. Specific Aim: Determine the feasibility of TRF without energy intake restriction in adults with ADPKD and overweight/obesity. The study will determine adherence to TRF by assessing the percent of participants achieving the goal of eating within an 8-hour TRF window, measured objectively with a photographic food record and verified with continuous glucose monitoring data. The study will also further assess the safety, acceptability, and tolerability of TRF by evaluation of safety labs, adverse events, and quality of life measures, as well as changes in abdominal adiposity and total kidney volume (TKV) by magnetic resonance imaging (MRI), and markers of biological pathways (AMP-activated protein kinase [AMPK], mTOR, insulin-like growth factor 1 [IGF1]).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: March 31, 2023
• Est. primary completion date: March 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Aged 18-65 years

2. ADPKD diagnosis based on the modified Pei-Ravine criteria

3. BMI 25-45 kg/m^2

4. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimated glomerular filtration rate =30 mL/min/1.73 m^2

5. Access to the internet with video chat capabilities and smartphone

6. Typical eating duration >12 hrs/day

7. Not currently participating in another interventional study or weight loss program

8. Ability to provide informed consent

Exclusion Criteria:

1. Diabetes mellitus (diagnosis or fasting glucose >126 mg/dL or Hemoglobin A1C >6.5%)

2. Current nicotine use or history of use in the past 12 months

3. Alcohol or substance abuse (self-report or undergoing treatment)

4. History of hospitalization or major surgery within the last 3 months

5. Untreated dyslipidemia (low density lipoprotein cholesterol > 190 mg/dL or triglycerides >400 mg/dL)

6. Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg)

7. Pregnancy, lactation, or unwillingness to use adequate birth control

8. Cardiovascular disease, peripheral vascular disease, cerebrovascular disease, significant pulmonary or gastrointestinal disease (described below), cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis)

9. Significant gastrointestinal disorders including: chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, ulcerative colitis, chronic diarrhea, or active gallbladder disease

10. Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism (e.g. appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants; study physician will be consulted as needed; antibiotics started during the intervention period are not an exclusion); regular use of obesity pharmacotherapeutic agents within the last 6 month

11. History of clinically diagnosed eating disorder including anorexia nervosa, bulimia, binge eating disorder. Score >20 on the Eating Attitudes Test (EATS)-2653 will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.

12. Weight loss >5% in past 3 months for any reason except post-partum weight loss; weight gain >5% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.

13. Untreated hyper- or hyperthyroidism (TSH outside of normal range for laboratory or history of uncontrolled thyroid disorder). History of thyroid disorder or current thyroid disease treated with stable medication regimen for at least 6 months in acceptable.

14. Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Score > 18 on the Beck Depression Inventory will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.

15. History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions.

16. Inability to cooperate with/clinical contraindication for MRI including severe claustrophobia, implants, devices, or non-removable body piercings

Related Conditions & MeSH terms

• Arthrogryposis
• Kidney Diseases
• Polycystic Kidney Diseases
• Polycystic Kidney, Autosomal Dominant

Intervention

Behavioral:
• Dietary
Dietary intake behavioral intervention via time restricted feeding and normal healthy eating recommendations vs. normal healthy eating recommendations without restricted

Locations

Country	Name	City	State
United States	University of Colorado - Anschutz Medical Campus	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	PKD Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in resting energy expenditure	Standard indirect calorimetry	1 year
Other	Change in energy intake	24-hr dietary recalls will be analyzed using a random day in the 7-day photographic food record/continuous glucose monitoring collection period to evaluate self-reported energy intake	1 year
Other	Change in macronutrient intake	24-hr dietary recalls will be analyzed using a random day in the 7-day photographic food record/CGM collection period to evaluate self-reported energy intake	1 year
Other	Change in self-reported physical activity	Self-reported physical activity will be quantified using the Stanford Physical Activity Questionnaire	1 year
Primary	Adherence	Percent adherence to the 8-hr TRF window (during the 7 day recordng period)	1 year
Primary	Feasibility to enroll participants	Numbers of individuals pre-screened and enrolled	Through study enrollment, an expected duration of 12 months
Primary	Feasibility to retain participants	Numbers of individuals retained	Through study completion, an expected duration of 24 months
Secondary	Safety and tolerability, measured as adverse events	Number of participants with treatment-related adverse events in each group as evaluated by the Safety Officer	Through study completion, an expected duration of 24 months
Secondary	Change in Body Weight	Body weight will be measured at baseline and monthly, using BodyTrace scales for remote, secure transmission of data.	1 year
Secondary	Change in Abdominal adiposity	Abdominal adiposity will be quantified using MRI	1 year
Secondary	Change in Body Composition	Body composition measured via dual-energy X-ray absorptiometry (DEXA)	1 year
Secondary	Change in insulin-like growth factor binding protein-1 levels	Fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) levels will be evaluated in each group	1 year
Secondary	Change in serum insulin-like growth factor-1 levels	Fasting serum insulin-like growth factor-1 (IGF-1) levels will be evaluated in each group	1 year
Secondary	Change in peripheral blood mononuclear cell (PBMC) AMPK expression	Peripheral blood mononuclear cell protein expression of AMP-activated kinase (AMPK) in each group	1 year
Secondary	Change in PBMC S6K expression	Peripheral blood mononuclear cell protein expression of S6 kinase (S6K) in each group	1 year
Secondary	Change in ß-hydroxybutyrate levels	Serum ß-hydroxybutyrate levels in each group	1 year
Secondary	Change in total kidney volume by magnetic resonance imaging (MRI)	Change in total kidney volume by MRI in each group	1 year
Secondary	Change in quality of life	Quality of life (QOL) will be assessed with the RAND 36 Item Health Survey (RAND-36) physical and mental health component summary score	1 year
Secondary	Change in mood	Mood state will be assessed with the Profile of Mood States 2 (POMS-2)	1 year
Secondary	Change in pain	Modified version of the Wisconsin Brief Pain Survey	1 year